Evidence map›Paper›PMID 36359321›Full record

ArticleBiomedicines2022

Prospective Clinical Evaluation of the Diagnostic Accuracy of a Highly Sensitive Rapid Antigen Test Using Silver Amplification Technology for Emerging SARS-CoV-2 Variants.

Kazuaki Obata, Kei Miyakawa, Toshiki Takei, Atsuhiko Wada, Yasuyoshi Hatayama, Hideaki Kato, Yayoi Kimura, Hisakuni Sekino, Junichi Katada, Akihide Ryo

Open access · goldAbstract read
In one paragraph

Article in Biomedicines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 55% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Kazuaki ObataSekino Hospital, Tokyo 171-0014, Japan.
Kei MiyakawaDepartment of Microbiology, Yokohama City University School of Medicine, Kanagawa 236-0004, Japan.
Toshiki TakeiMedical Systems Research & Development Center, FUJIFILM Corporation, Kanagawa 258-8538, Japan.
Atsuhiko WadaMedical Systems Research & Development Center, FUJIFILM Corporation, Kanagawa 258-8538, Japan.
Yasuyoshi HatayamaDepartment of Microbiology, Yokohama City University School of Medicine, Kanagawa 236-0004, Japan.
Hideaki KatoInfection Prevention and Control Department, Yokohama City University Hospital, Kanagawa 260-0004, Japan.ORCID 0000-0002-7853-5721
Yayoi KimuraAdvanced Medical Research Center, Yokohama City University, Kanagawa 236-0004, Japan.
Hisakuni SekinoSekino Hospital, Tokyo 171-0014, Japan.
Junichi KatadaMedical Systems Research & Development Center, FUJIFILM Corporation, Kanagawa 258-8538, Japan.
Akihide RyoDepartment of Microbiology, Yokohama City University School of Medicine, Kanagawa 236-0004, Japan.
Fujifilm (Japan) · JPYokohama City University · JPKomagino Hospital · JPYokohama City University Hospital · JPYokohama City University Medical Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The COVID-19 pandemic caused by SARS-CoV-2 remains a serious health concern worldwide due to outbreaks of SARS-CoV-2 variants that can escape vaccine-acquired immunity and infect and transmit more efficiently. Therefore, an appropriate testing method for COVID-19 is essential for effective infection control and the prevention of local outbreaks. Compared to reverse-transcription polymerase chain reaction (RT-PCR) tests, antigen tests are used for simple point-of-care testing, enabling the identification of viral infections. In this study, we tested the clinical usefulness of the FUJIFILM COVID-19 Ag test, an antigen test based on silver amplification and immunochromatographic technology. The FUJIFILM COVID-19 Ag test was shown to detect a lower viral concentration as compared to other conventional kits without significant performance loss in detecting prevalent SARS-CoV-2 variants. We tested nasopharyngeal and nasal swabs from a single patient during two different epidemic periods dominated by various SARS-CoV-2 variants. We observed that the sensitivity of the FUJIFILM COVID-19 Ag test was 95.7% and 85.7% in nasopharyngeal and nasal swabs, respectively. These results suggest that the FUJIFILM COVID-19 Ag test is highly sensitive and applicable when RT-PCR testing is unavailable. Furthermore, these results indicate that high-frequency testing using nasal swab specimens may be a valuable screening strategy.

Indexed as

COVID-19diagnostic performance studyrapid antigen testSARS-CoV-2

Identifiers

PMID36359321
PMCPMC9687987
OpenAlexW4308630795

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.